There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vaxart (VXRT – Research Report) and Palisade Bio (PALI – Research Report) with bullish sentiments.
Vaxart (VXRT)
In a report released today, Mayank Mamtani from B.Riley Financial upgraded Vaxart to Buy, with a price target of $2.00. The company’s shares closed last Tuesday at $0.98.
According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vaxart with a $2.00 average price target.
See today’s best-performing stocks on TipRanks >>
Palisade Bio (PALI)
Maxim Group analyst Naz Rahman maintained a Buy rating on Palisade Bio yesterday and set a price target of $1.50. The company’s shares closed last Tuesday at $0.62, close to its 52-week low of $0.50.
According to TipRanks.com, Rahman is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Palisade Bio is a Moderate Buy with an average price target of $1.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VXRT:
- Biotech Alert: Searches spiking for these stocks today
- Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
- Vaxart receives $9.27M BARDA project award for Phase 2B trial on oral pill
- Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
- Vaxart CEO Andrei Floroiu resigns, Michael Finney named interim
